ABVD regimen: Difference between revisions

	WikiDoc Resources for ABVD regimen
Articles
Most recent articles on ABVD regimen Most cited articles on ABVD regimen Review articles on ABVD regimen Articles on ABVD regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on ABVD regimen Images of ABVD regimen Photos of ABVD regimen Podcasts & MP3s on ABVD regimen Videos on ABVD regimen
Evidence Based Medicine
Cochrane Collaboration on ABVD regimen Bandolier on ABVD regimen TRIP on ABVD regimen
Clinical Trials
Ongoing Trials on ABVD regimen at Clinical Trials.gov Trial results on ABVD regimen Clinical Trials on ABVD regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on ABVD regimen NICE Guidance on ABVD regimen NHS PRODIGY Guidance FDA on ABVD regimen CDC on ABVD regimen
Books
Books on ABVD regimen
News
ABVD regimen in the news Be alerted to news on ABVD regimen News trends on ABVD regimen
Commentary
Blogs on ABVD regimen
Definitions
Definitions of ABVD regimen
Patient Resources / Community
Patient resources on ABVD regimen Discussion groups on ABVD regimen Patient Handouts on ABVD regimen Directions to Hospitals Treating ABVD regimen Risk calculators and risk factors for ABVD regimen
Healthcare Provider Resources
Symptoms of ABVD regimen Causes & Risk Factors for ABVD regimen Diagnostic studies for ABVD regimen Treatment of ABVD regimen
Continuing Medical Education (CME)
CME Programs on ABVD regimen
International
ABVD regimen en Espanol ABVD regimen en Francais
Business
ABVD regimen in the Marketplace Patents on ABVD regimen
Experimental / Informatics
List of terms related to ABVD regimen

VisualWikitext

Latest revision as of 13:43, 11 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: ABVD; ABVD regimen; Adriamycin-Bleomycin-Vinblastine-Dacarbazine regimen; BLEO/DOX/DTIC/VBL; Bleomycin/Dacarbazine/Doxorubicin/Vinblastine regimen

Overview

ABVD regimen refers to an a chemotherapy regimen consisting of doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine and dacarbazine, used alone or in combination with radiation therapy, for the primary treatment of Hodgkin lymphoma.^[1]^[2]

Regimen

ADoxorubicin (Adriamycin)

BBleomycin

VVinblastine

DDacarbazine

Indications

Primary treatment of Hodgkin's lymphoma ^[3]

References

↑ "NCI Thesaurus".
↑ "R-CHOP - National Cancer Institute".
↑ Nagai H (2014). "[Hodgkin lymphoma]". Nihon Rinsho. 72 (6): 1099–103. PMID 25016811.

[1] "NCI Thesaurus".

[2] "R-CHOP - National Cancer Institute".

[pmid25016811-3] Nagai H (2014). "[Hodgkin lymphoma]". Nihon Rinsho. 72 (6): 1099–103. PMID 25016811.

[1]

[2]

[3]

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{AV}}
-{{SK}} Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen
+{{SK}} ABVD; ABVD regimen; Adriamycin-Bleomycin-Vinblastine-Dacarbazine regimen; BLEO/DOX/DTIC/VBL; Bleomycin/Dacarbazine/Doxorubicin/Vinblastine regimen
 ==Overview==
-{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[rituximab]], [[cyclophosphamide]], [[doxorubicin |hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride)]], [[vincristine|vincristine (Oncovin)]] and [[prednisone]] used to treat both indolent and aggressive forms of [[non-Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
+{{PAGENAME}} refers to an  a chemotherapy regimen consisting of [[doxorubicin|doxorubicin hydrochloride (Adriamycin)]], [[bleomycin]], [[vinblastine]] and [[dacarbazine]], used alone or in combination with radiation therapy, for the primary treatment of [[Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
 ==Regimen==
-[[Rituximab|{{button|R – Rituximab}}]]
+{{chemo|A|Doxorubicin (Adriamycin)}}
-[[Cyclophosphamide|{{button|C – Cyclophosphamide}}]]
+{{chemo|B|Bleomycin}}
-[[Doxorubicin|{{button|H – Doxorubicin (Hydroxydaunomycin)}}]]
+{{chemo|V|Vinblastine}}
-[[Vincristine|{{button|O – Vincristine (Oncovin)}}]]
+{{chemo|D|Dacarbazine}}
-[[Prednisone|{{button|P – Prednisone}}]]
 ==Indications==
-* [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma, untreated]]<ref>{{Cite journal | doi = 10.1056/NEJMoa011795 | issn = 1533-4406 | volume = 346 | issue = 4 | pages = 235–242 | last = Coiffier | first = Bertrand | coauthors = Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht | title = CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | journal = The New England Journal of Medicine | date = 2002-01-24 | pmid = 11807147 }}</ref>
+* Primary treatment of [[Hodgkin's lymphoma]] <ref name="pmid25016811">{{cite journal| author=Nagai H| title=[Hodgkin lymphoma]. | journal=Nihon Rinsho | year= 2014 | volume= 72 | issue= 6 | pages= 1099-103 | pmid=25016811 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25016811  }} </ref>
-* [[Mantle cell lymphoma]]<ref>{{Cite journal | doi = 10.1056/NEJMoa1200920 | issn = 1533-4406 | volume = 367 | issue = 6 | pages = 520–531 | last = Kluin-Nelemans | first = H. C. | coauthors = E. Hoster, O. Hermine, J. Walewski, M. Trneny, C. H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J. K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J. M. Zijlstra, R. Bouabdallah, P. J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Procházka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. André, W. Klapper, W. Hiddemann, M. Unterhalt, M. H. Dreyling | title = Treatment of older patients with mantle-cell lymphoma | journal = The New England Journal of Medicine | date = 2012-08-09 | pmid = 22873532 }}</ref>
 ==References==
 {{Reflist|2}}
 [[Category:Chemotherapy regimens]]